The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the ...

The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.

Mpox, declared a global public health emergency by WHO, has disproportionately affected children and adolescents ...

With more than 200 mpox-related deaths reported globally, the EMA has approved Imvanex for adolescents aged 12-17 years.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s ...

LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in ...

(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II ...

Paul Chaplin, President & CEO of Bavarian Nordic, said: "We applaud EMA for their expedited review and decision to recommend approval of MVA-BN for adolescents. This represents an important milestone ...

The European Commission has greenlit Bavarian Nordic’s mpox and smallpox vaccine for approval for kids aged 12 to 17. The European Medicines Agency carried out an expedited and positive review of the ...

Bavarian Nordic's mpox vaccine has gained approval for use in adolescents by the EU's drug regulator. This move is seen as ...

The European Commission has approved Bavarian Nordic's (OTCPK:BVNRY)(OTCPK:BVNKF) mpox shot for adolescents between 12 and 17 ...

LONDON, Sept 19 (Reuters) - The EU's drug regulator has approved Bavarian Nordic's (BAVA.CO), opens new tab mpox vaccine for ...